HRTIS Herantis Pharma Oyj

Herantis Pharma publishes newsletter for May-June

Herantis Pharma publishes newsletter for May-June

Herantis Pharma publishes newsletter for May-June

Herantis Pharma Plc

Press release 1 July 2019 at 9:00 am

Herantis Pharma plc (“Herantis”) has published its newsletter for May-June 2019. The newsletter is also attached to this press release.

Herantis’ newsletter is published every other month on the company’s . It is also available by .

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: 5

Company web site:

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Main media

 

Attachment

EN
01/07/2019

Underlying

HRTISHerantis Pharma Oyj

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Herantis Pharma Oyj

 PRESS RELEASE
Free
HRTIS Herantis Pharma...

Herantis Pharma releases 2H and FY 2025 report today

Herantis Pharma releases 2H and FY 2025 report today Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 2H and FY 2025 report. The full report is attached to this release and is also available on the Company’s website: . Commenting on the results, Antti Vuolanto, CEO of Herantis Pharma, said: “2025 was a year of significant progress for Herantis Pharma, highlighted by ...

2h / 25m 1 EN
 PRESS RELEASE
Free
HRTIS Herantis Pharma...

Inside information: Herantis Pharma selected for Horizon 2025 grant of...

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096 Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage biotech company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces that it is leading a consortium that has been selected for, pending final negotiation, an EUR 8.0 million grant from the Horizon ...

February 19, 2026 1 EN
 PRESS RELEASE
Free
HRTIS Herantis Pharma...

Herantis Pharma - Phase 1b biomarker data show clear evidence of biolo...

Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show that HER-096 modulates Parkinson’s disease-relevant pathways, consistent with preclinical data, and supporting further clinical developmentHER-096 exposure was associated with changes across key disease-related pathways, including proteostasis, mitochondr...

January 7, 2026 1 EN
 PRESS RELEASE
Free
HRTIS Herantis Pharma...

Herantis Pharma announces successful completion of six-month GLP toxic...

Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096 Key step achieved in advancing HER-096 towards Phase 2 efficacy trial  Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previou...

November 26, 2025 1 EN
 PRESS RELEASE
Free
HRTIS Herantis Pharma...

Herantis Pharma presents positive topline data for HER-096 in Phase 1b...

Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong foundation to Phase 2  The clinical trial demonstrated that both repeated 200 mg and 300 mg doses of HER-096 are generally safe and well tolerated in Parkinson’s disease (PD) patients.Results from the clinical trial demonstrated a pharmacokinetic profile consistent with predictions...

October 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch